Back to All Team Members

Greg Zaic

Advisor to the Board

Greg Zaic is currently a general partner of Nexus Medical & Technology Capital (“Nexus”), a venture capital firm specializing in healthcare technology investments. He has over 25 years of venture capital investment experience.

Greg has been an active Board member of both public and private corporations, providing assistance and guidance on issues associated with business strategy, corporate expansion, corporate combinations and organizational development. He currently represents Nexus on the Boards of Sabal Medical (hospital medication tracking, recently bought by Swisslog), Zipit Wireless (smart pagers for hospitals, partnered with Verizon), Aethon Inc. (hospital-based robotic logistics), Kiyatec Inc. (3-D cell culture) and Cutanea Life Sciences (dermatological pharmaceuticals, recently bought by Maruho Corporation, Osaka, Japan).

About Greg 

Greg's recent speaking engagements include:

  • Life Sciences & Healthcare Venture Summit (New York City, 2013, 2009)
  • IN3 East Investment in Innovation (Boston, 2012, 2011 and 2010)
  • Crossroads of Ideas and Capital: Vision 2015 (New Haven, 2011)
  • New England Venture Summit (Boston, 2010)
  • Health Science South Carolina (Columbia, SC, 2010)
  • Southeast Region Angel Capital Association Meeting (Greenville, SC, 2010)
  • 5th Annual South Carolina MedTech Conference (Greenville, SC, 2009)
  • Life Science and Healthcare Venture Summit (Boston, 2009)
  • Biomedix 2006 (Montreal)
  • 2005 Congrès Réseau Capital (Quebec City)


Prior to joining Nexus, Greg was a general partner of Prince Ventures, an independent, medically focused, venture capital partnership.

Greg's investments included PerSeptive Biosystems (bioseparations products) that was sold to Perkin Elmer for over $300 million.

During the 1980s, Greg was Vice President and Special Limited Partner of the Vista Group. He was a founding investor in numerous successful companies including Focus Healthcare, an HMO that was sold to Lincoln National Insurance Company for a substantial return.

From 1972 to 1979, Greg was an executive with Baxter Laboratories. His three member team was responsible for bringing CAPD (Continuous Ambulatory Peritoneal Dialysis) into Baxter, where it became the second-most profitable product line in the company, then accounting for approximately 20% of Baxter’s total profits.

Greg was responsible for Nexus’ successful investment in Biodel Inc., a company developing a new formulation of insulin. He maintains offices in Greenville, SC, Ridgefield, CT and Quincy, MA.

Greg received a BS (magna cum laude) in aerospace and mechanical engineering from Princeton University; an MS in mechanical engineering from the Massachusetts Institute of Technology (MIT); and an MS from MIT’s Sloan School of Management.

Expert In